Lead-Discovery-Center



Newsletter abonnieren
Empfangen Sie aktuelle Informationen über
das LDC

Fachzeitschriften

2017

Picomolar, selective and subtype specific small-molecule inhibition of TRPC1/4/5 channels

Hussein N Rubaiy, Melanie J Ludlow, Matthias Henrot, Hannah J Gaunt, Katarina Miteva, Sin Yin Cheung, Yasuyuki Tanahashi1,Nurasyikin Hamzah, Katie E Musialowski, Nicola M Blythe, Hollie L Appleby, Marc A Bailey, Lynn McKeown, Roger Taylor, Richard Foster, Herbert Waldmann, Peter Nussbaumer, Mathias Christmann, Robin S Bon, Katsuhiko Muraki, David J
Beech

Published on March 21, 2017 as Manuscript M116.773556

>> Picomolar, selective, and subtype specific small-molecule inhibition of TRPC1/4/5 channels

 

2016

Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site

Murarka S, Martín-Gago P, Schultz-Fademrecht C, Al Saabi A, Baumann M, Fansa EK, Ismail S, Nussbaumer P, Wittinghofer A, Waldmann H.
Chemistry. 2016 Nov 3. doi: 10.1002/chem.201603222.

 

Design and synthesis of DNA-encoded libraries based on a benzodiazepine and a pyrazolopyrimidine scaffold

Škopić MK, Bugain O, Jung K, Onstein S, Brandherm S, Kalliokoski T, Brunschweiger A.
MedChemComm, 2016, doi: 10.1039/C6MD00243A.

 

Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics

Chakedis J, French R, Babicky M, Jaquish D, Mose E, Cheng P, Holman P, Howard H, Miyamoto J, Porras P, Walterscheid Z, Schultz-Fademrecht C, Esdar C, Schadt O, Eickhoff J, Lowy AM.

Oncotarget. 2016 Jun 14. doi: 10.18632/oncotarget.10009. [Epub ahead of print]. PMID: 27323855.

 

Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models

Fischer W, Franke H, Krügel U, Müller H, Dinkel K, Lord B, Letavic MA, Henshall DC, Engel T.
PLoS One. 2016 Jun 9;11(6).

 

Identification of pyrazolopyridazinones as PDEδ inhibitors

Papke B, Murarka S, Vogel HA, Martín-Gago P, Kovacevic M, Truxius DC, Fansa EK, Ismail S, Zimmermann G, Heinelt K, Schultz-Fademrecht C, Al Saabi A, Baumann M, Nussbaumer P, Wittinghofer A, Waldmann H, Bastiaens PI.
Nat Commun. 2016 Apr 20;7:11360. doi: 10.1038/ncomms11360.

 

The Evolving Role of the Medicinal Chemist

Prog Med Chem. 2016;55:193-226. doi: 10.1016/bs.pmch.2015.11.001. Epub 2016 Jan 15.
Lawton G, Nussbaumer P.

 

2015

Expansion of Chemical Space for Collaborative Lead Generation and Drug Discovery: The European Lead Factory Perspective

Anna Karawajczyk, Fabrizio Giordanetto, Jorg Benningshof, Daniel Hamza, Tuomo Kalliokoski, Kees Pouwer, Remy Morgentin, Adam Nelson, Gerhard Müller, Alexander Piechot and Dimitrios Tzalis.

(Nov 2015): 1310-16.doi:10.1016/j.drudis.2015.09.009

>> PDF zum Download

 

Medicinal Chemists of the 21st Century – Who Are We and Where to Go?

Dr. Peter Nussbaumer

ChemMedChem 2015, 10(7), 1133-1139

 

Professional translational research: a new hybrid paradigm in early drug discovery

Dr. Peter Nussbaumer, Dr. Bert Klebl

Future science group; Future Medicinal Chemistry

Vol. 7, No. 14, Pages 1879-1889, DOI 10.4155/fmc.15.124 (doi:10.4155/fmc.15.124)

>> Professional translational research: a new hybrid paradigm in early drug discovery

 

Price-Focused Analysis of Commercially Available Building Blocks for Combinatorial Library Synthesis

Tuomo Kalliokoski

ACS Comb. Sci, Article ASAP DOI: 10.1021/ arscombsci.5b00063

 

Protein-protein interactions as drug targets

Malgorzata Skwarczynska and Christian Ottmann

Future Med Chem. 2015;7(16):2195-219. doi: 10.4155/fmc.15.138.

 

 

Aminomethylhydroxylation of alkenes: Exploitation in the synthesis of scaffolds for small molecule libraries

Ignacio Colomer, Ololade Adeniji, George M. Burslem, Philip Craven, Martin Ohsten Rasmussen, Anthony Willaume, Tuomo Kalliokoski, Richard Foster, Stephen P. Marsden, Adam Nelson

Bioorganic & Medicinal Chemistry 23 (2015) 2629–2635, journal homepage: www.elsevier.com/locate/bmc

>> PDF zum Download

 

A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations

Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeitträger I, Bahsi H, Wagner S, Zischinsky G, Wolf A, Degenhart C, Unger A, Baumann M, Klebl B, Marschall M.

Antimicrob. Agents Chemother. 2015 Apr;59(4):2062-71. doi: 10.1128/AAC.04534-14. Epub 2015 Jan 26.

>> PDF zum Download

 

Selective inhibitors of the FK506-binding protein 51 by induced fit

Gaali S, Kirschner A, Cuboni S, Hartmann J, Kozany C, Balsevich G, Namendorf C, Fernandez-Vizarra P2, Sippel C1, Zannas AS, Draenert R4, Binder EB, Almeida OF, Rühter G6, Uhr M1, Schmidt MV, Touma C, Bracher A, Hausch F.
Nat Chem Biol. 2015 Jan;11(1):33-7. doi: 10.1038/nchembio.1699. Epub 2014 Dec 1.

 

2014

Design, synthesis and decoration of molecular scaffolds for exploitation in the production of alkaloid-like libraris

Philip Craven, Anthony Aimon, Mark Dow, Nicolas Fleury-Bregeot, Rachel Guilleux, Remy Morgentin, Didier Roche, Tuomo Kalliokoski, Richard Foster, Stephen P. Marsden, Adam Nelson

Bioorganic & Medicinal Chemistry 23 (2015) 2629–2635, journal homepage: www.elsevier.com/locate/bmc

>> PDF zum Download

 

Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells

Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, Klebl B, Meisterernst M.

Mol Cell Biol. 2014 Oct 1;34(19):3675-88. doi: 10.1128/MCB.00595-14. Epub 2014 Jul 21.

 

Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site

Zimmermann G, Schultz-Fademrecht C, Küchler P, Murarka S, Ismail S, Triola G, Nussbaumer P, Wittinghofer A, Waldmann H.

J Med Chem. 2014 Jun 26;57(12):5435-48. doi: 10.1021/jm500632s. Epub 2014 Jun 11.

 

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa JP, Cronin SJ, Nitsch R, Schultz-Fademrecht C, Eickhoff J, Menninger S, Unger A, Torka R, Gruber T, Hinterleitner R, Baier G, Wolf D, Ullrich A, Klebl BM, Penninger JM.

Nature. 2014 Mar 27;507(7493):508-12. doi: 10.1038/nature12998. Epub 2014 Feb 19.

 

Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor

Albert T.K., Rigault C., Eickhoff J., Baumgart K., Antrecht C., Klebl B., Mittler G., Meisterernst M.

Br. J. Pharmacol. 2014; Jan;171(1):55-68. doi: 10.1111/bph.12408

 

2013

An acetylome peptide microarray reveals specificities and deacetylation substrates for all human sirtuin isoforms

Rauh D., Fischer F., Gertz M., Lakshminarasimhan M., Bergbrede T., Aladini F., Kambach C., Becker CF., Zerweck J., Schutkowski M., Steegborn C.

Nat Commun. 2013 Sep 2;4:2327. doi: 10.1038/ncomms3327

 

Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design

Richters A., Ketzer J., Getlik M., Grütter C., Schneider R., Heuckmann JM., Heynck S., Sos ML., Gupta A., Unger A., Schultz-Fademrecht C., Thomas RK., Bauer S., Rauh D.

J Med Chem. 2013 Jul 10

 

Stabilization of physical RAF/14-3-3 interaction by Cotylenin A as treatment strategy for RAS mutant cancers

Molzan M., Kasper S., Röglin L., Skwarczynska M., Sassa T., Inoue T., Breitenbuecher F., Ohkanda J., Kato N., Schuler M., Ottmann C.

ACS Chem Biol. 2013 Jul 5

 

Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface

De Vries-van Leeuwen IJ, da Costa Pereira D, Flach KD, Piersma SR, Haase C, Bier D, Yalcin Z, Michalides R, Feenstra KA, Jiménez CR, de Greef TF,Brunsveld L, Ottmann C, Zwart W, de Boer AH

Proc Natl Acad Sci U S A. 2013 May 28;110(22):8894-9. doi: 10.1073/pnas.1220809110. Epub 2013 May 15

 

Cheminformatics at the interface of medicinal chemistry and proteomics

Koch U., Hamacher M., Nussbaumer P.

Biochimica et Biophysica Acta 2013; May 21. pii: S1570-9639(13)00207-0. doi: 10.1016/j.bbapap.2013.05.010

 

Derivation of injury-responsive dendritic cells for acute brain targeting and therapeutic protein delivery in the stroke-injured rat

Manley NC., Caso JR., Works MG., Cutler AB., Zemlyak I., Sun G., Munhoz CD., Chang S., Sorrells SF., Ermini FV., Decker JH., Bertrand AA., Dinkel K., Steinberg GK., Sapolsky RM.

PLoS One. 2013 Apr 16;8(4)

 

Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian Neurodegeneration to ERK-Dependent Changes in Gene Expression

Peter Reinhardt, Benjamin Schmid, Lena F. Burbulla, David C. Schöndorf, Lydia Wagner, Michael Glatza, Susanne Höing, Gunnar Hargus, Susanna A. Heck, Ashutosh Dhingra, Guangming Wu, Stephan Müller, Kathrin Brockmann, Torsten Kluba, Martina Maisel, Rejko Krüger, Daniela Berg, Yaroslav Tsytsyura, Cora S. Thiel, Olympia-Ekaterini Psathaki, Jürgen Klingauf, Tanja Kuhlmann, Marlene Klewin, Heiko Müller, Thomas Gasser, Hans R. Schöler, Jared Sterneckert

Cell Stem Cell – 7 March 2013 (Vol. 12, Issue 3, pp. 354-367)

 

 

Activation of NF-κB signalling by fusicoccin-induced dimerization

Skwarczynska M., Molzan M., Ottmann C.

Proc Natl Acad Sci USA. 2013 Jan 29;110 (5):E377-86. doi: 10.1073/pnas.1212990110

 

Increasing the Efficiency of Ligands for FK506-Binding Protein 51 by Conformational Control

Wang Y., Kirschner A., Fabian AK., Gopalakrishnan R., Kress C., Hoogeland B., Koch, U., Kozany C., Bracher A., Hausch F.

Med Chem. 2013; 56(10), pp 3922-35

 

2012

Development of Selective, Potent RabGGTase Inhibitors

Stigter EA, Guo Z, Bon RS, Wu YW, Choidas A, Wolf A, Menninger S, Waldmann H, Blankenfeldt W, Goody RS.

J Med Chem. 2012 Oct 11;55(19):8330-40. doi: 10.1021/jm300624s. Epub 2012 Oct 3. [Epub ahead of print] PMID: 22963166

 

Amorfrutins are potent antidiabetic dietary natural products

Weidner C, de Groot JC, Prasad A, Freiwald A, Quedenau C, Kliem M, Witzke A, Kodelja V, Han CT, Giegold S, Baumann M, Klebl B, Siems K, Müller-Kuhrt L, Schürmann A, Schüler R, Pfeiffer AF, Schroeder FC, Büssow K, Sauer S.

Proc Natl Acad Sci USA 2012, 109(19), 7257-62

 

Psoromic Acid is a Selective and Covalent Rab-Prenylation Inhibitor Targeting Autoinhibited RabGGTase

Deraeve C, Guo Z, Bon RS, Blankenfeldt W, DiLucrezia R, Wolf R, Choidas A, Wetzel S, Alexandrov K, Waldmann H, Goody RS, Wu Y.

J Am Chem Soc. 2012 May 2;134(17):7384-91.

 

2011

Natural product-inspired cascade synthesis yields modulators of centrosome integrity

Dückert H, Pries V, Khedkar V, Menninger S, Bruss H, Bird AW, Maliga Z, Brockmeyer A, Janning P, Hyman A, Grimme S, Schürmann M, Preut H, Hübel K, Ziegler S, Kumar K, Waldmann H.
Nat Chem Biol. 2011 Dec 25;8(2):179-84. doi: 10.1038/nchembio.758.

 

Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1

Feichtinger S, Stamminger T, Müller R, Graf L, Klebl B, Eickhoff J, Marschall M.
J Gen Virol. 2011 Jul;92(Pt 7):1519-31. Epub 2011 Mar 30.

 

Structure-guided development of selective RabGGTase inhibitors

Bon RS, Guo Z, Stigter EA, Wetzel S, Menninger S, Wolf A, Choidas A, Alexandrov K, Blankenfeldt W, Goody RS, Waldmann H.
Angew Chem Int Ed Engl. 2011 May 16;50(21):4957-61. doi: 10.1002/anie.201101210. Epub 2011 Apr 21. No abstract available.

 

Total synthesis and biological evaluation of (-)-englerin A and B: synthesis of analogues with improved activity profile

Radtke L, Willot M, Sun H, Ziegler S, Sauerland S, Strohmann C, Fröhlich R, Habenberger P, Waldmann H, Christmann M.
Angew Chem Int Ed Engl. 2011 Apr 18;50(17):3998-4002. doi: 10.1002/anie.201007790. Epub 2011 Mar 29. No abstract available.

 

Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6Hindolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase

Narjes F., Crescenzi B., Ferrara M., Habermann J,Colarusso S., Ferreira M. del R., Stansfield I., MackayA.C., Conte I., Ercolani C., Zaramella S., Koch U., Migliaccio G., Altamura S., Laufer R., De Francesco R., Rowley M.
Med Chem. 2011 Jan 13;54(1):289-301.

 

2010

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer

Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sänger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nürnberg P, Perner S, Thomas RK.
Sci Transl Med. 2010 Dec 15;2(62):62ra93. Erratum in: Sci Transl Med. 2011 Jan 19;3(66):66er2. PubMed PMID: 21160078

 

A flexible multiwell format for immunofluorescence screening microscopy of small-molecule inhibitors

Scholz AK, Klebl BM, Morkel M, Lehrach H, Dahl A, Lange BM.
Assay Drug Dev Technol. 2010 Oct;8(5):571-80. Epub 2010 Jul 28.

 

Small-molecule inhibition of APT1 affects Ras localization and signaling

Dekker FJ, Rocks O, Vartak N, Menninger S, Hedberg C, Balamurugan R, Wetzel S, Renner S, Gerauer M, Schölermann B, Rusch M, Kramer JW, Rauh D, Coates GW, Brunsveld L, Bastiaens PI, Waldmann H.
Nat Chem Biol. 2010 Jun;6(6):449-56. Epub 2010 Apr 25.

 

2009

From Fragment Screening to Potent Binders: Strategies for Fragment-to-Lead Evolution.

Eitner K, Koch U. – Mini Rev Med Chem. 2009 Jul;9(8):956-61.

 

Data handling and processing in proteomics

Hamacher M, Stephan C, Meyer HE, Eisenacher M. – Expert Rev Proteomics. 2009 Jun;6(3):217-9

 

Unterstützung der Identifizierung von Leitstrukturen mit PBMCs

Peter Habenberger, Axel Choidas, Bert Klebl, Jan Eickhoff
LaborWelt Nr. 4/2009 – 10. Jahrgang,
Seiten 4 – 6

>> PDF zum Download

 

2008

Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition

Backes A.C., Zech B., Felber B., Klebl B., Müller G. – Expert Opin. Drug Discov. 2008; 3, 1409-1425.

 

Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition

AC Backes, B Zech, B Felber, B Klebl, G Muller – Expert Opin. Drug Discov., 2008

 

 

Bücher

Protein Kinases as Drug Targets: 49 (Methods and Principles in Medicinal Chemistry)

von Bert Klebl, Gerhard Müller und Michael Hamacher
Wiley-VCH Verlag GmbH & Co. KGaA

(Gebundene Ausgabe – 9. Februar 2011)

 

Screening for Kinase Inhibitors: From Biochemical to Cellular Assays

Eickhoff J., Choidas A in

Medicinal Chemistry 2011, Vol. 49, 45-67